Insurance Medicine

Prostate cancer is a significant disease—approximately 10 percent of men will be diagnosed with prostate cancer in their lifetime and the lifetime risk of dying of the disease is three percent.

Synthetic biotics show significant promise to prevent, diagnose, and treat diseases and improve future mortality and morbidity rates. If these new therapies successfully enter the market in the coming years, they are likely to help transform modern medicine.

In the past few decades, groundbreaking advances have emerged in early diagnosis, treatment, and management of cystic fibrosis (CF), and those with the condition are now living to age 60 and beyond. Why, then, are life insurance companies not yet offering terms to those living with CF?

RGA's Dr. Radi Counsell reviews how modern immunotherapy is transforming cancer outcomes, and the real possibility that it might even cure some highly lethal cancers such as malignant melanoma

Insurance Updates and Insights into HIV Infection

Understanding the impact of Long COVID has presented any number of difficulties, not only to the medical fraternity but also to insurers. There have been widely varying reports of the prevalence; from 10 to 90%. One pundit estimated between 4.5 and 27 million Americans will experience the effects of Long COVID.
 

Diabetes management is advancing in many areas. One such area is the glucose control concept. Evidence suggests that HbA1C will no longer be the sole glucose control marker utilized in the management of this disease – an expanded approach with novel drugs and more frequent glucose monitoring is set to substantially improve diabetes mortality and morbidity risk.
 

What if people could be screened for more types of cancer with a single test?
 

Recent developments and advances in the understanding and classification of colorectal polyps have been significant. This article will outline changes in terminology and nomenclature.

RGA's Colin M. DeForge, Dr. Valerie Kaufman, and Lauren Garfield, Ph.D. review the background, epidemiology, etiology, and prognosis of colorectal cancer (CRC), a cancer common in terms of incidence and mortality.